Literature DB >> 6339408

Antibody response after influenza immunization in renal transplant patients receiving cyclosporin A or azathioprine.

K L Huang, J A Armstrong, M Ho.   

Abstract

Nineteen renal transplant recipients receiving cyclosporin A and prednisone, eight kidney recipients receiving azathioprine and prednisone, and 12 healthy volunteers were immunized with 0.5 ml of trivalent influenza vaccine containing A/Bangkok/1/79 (H(3)N(2)), A/Brazil/11/78 (H(1)N(1)), and B/Singapore/222/79. Nine patients (47%) in the cyclosporin A group and five (63%) in the azathioprine group showed fourfold rises in titer to at least one virus strain compared with 12 (100%) in the control group.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6339408      PMCID： PMC264864          DOI： 10.1128/iai.40.1.421-424.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  23 in total

1.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

2.  The influence of cortisone and hydrocortisone on the production of circulating antibody in human beings.

Authors:  H T FRIEDMAN
Journal:  J Allergy       Date:  1953-07

3.  Corticosteroids and immunoglobulin synthesis.

Authors:  W T Butler
Journal:  Transplant Proc       Date:  1975-03       Impact factor: 1.066

4.  The effects of ACTH and cortisone on antibodies in human beings.

Authors:  G S MIRICK
Journal:  Bull Johns Hopkins Hosp       Date:  1951-04

5.  The effect of ACTH and cortisone on the concentration of circulating diphtheria antitoxin.

Authors:  W P HAVENS; J M SHAFFER; C J HOPKE
Journal:  J Immunol       Date:  1952-04       Impact factor: 5.422

6.  Effect of cyclosporin A on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR.

Authors:  A D Hess; P J Tutschka
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

7.  Effect of cyclosporin A on T-dependent and T-independent immunoglobulin synthesis in vitro.

Authors:  T Paavonen; P Häyry
Journal:  Nature       Date:  1980-10-09       Impact factor: 49.962

8.  Summary of clinical trials of influenza virus vaccines in adults.

Authors:  P D Parkman; H E Hopps; S C Rastogi; H M Meyer
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

9.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

10.  Effect of dosage and route of inoculation upon antigenicity of inactivated influenza virus vaccine (Hong Kong strain) in man.

Authors:  N M Tauraso; R Gleckman; F A Pedreira; J Sabbaj; R Yahwak; M A Madoff
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408
View more
  8 in total

1.  Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.

Authors:  A Holvast; A Huckriede; J Wilschut; G Horst; J J C De Vries; C A Benne; C G M Kallenberg; M Bijl
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

Review 2.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

3.  Seasonal maintenance of influenza vaccine-induced antibody response in kidney transplant recipients.

Authors:  Kelly A Birdwell; Mine R Ikizler; Li Wang; Daniel W Byrne; Edith C Sannella; Peter F Wright; T Alp Ikizler
Journal:  Am J Nephrol       Date:  2012-08-17       Impact factor: 3.754

Review 4.  Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective.

Authors:  Charles R Beck; Bruce C McKenzie; Ahmed B Hashim; Rebecca C Harris; Arina Zanuzdana; Gabriel Agboado; Elizabeth Orton; Laura Béchard-Evans; Gemma Morgan; Charlotte Stevenson; Rachel Weston; Mitsuru Mukaigawara; Joanne Enstone; Glenda Augustine; Mobasher Butt; Sophie Kim; Richard Puleston; Girija Dabke; Robert Howard; Julie O'Boyle; Mary O'Brien; Lauren Ahyow; Helene Denness; Siobhan Farmer; Jose Figureroa; Paul Fisher; Felix Greaves; Munib Haroon; Sophie Haroon; Caroline Hird; Rachel Isba; David A Ishola; Marko Kerac; Vivienne Parish; Jonathan Roberts; Julia Rosser; Sarah Theaker; Dean Wallace; Neil Wigglesworth; Liz Lingard; Yana Vinogradova; Hiroshi Horiuchi; Javier Peñalver; Jonathan S Nguyen-Van-Tam
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

Review 5.  Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy.

Authors:  Nina M Bemben; Melody L Berg
Journal:  Pharmacotherapy       Date:  2022-02-18       Impact factor: 6.251

6.  Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study.

Authors:  Kelly A Birdwell; Mine R Ikizler; Edith C Sannella; Li Wang; Daniel W Byrne; T Alp Ikizler; Peter F Wright
Journal:  Am J Kidney Dis       Date:  2009-01-29       Impact factor: 8.860

7.  Pathogenicity of pandemic H1N1 influenza A virus in immunocompromised cynomolgus macaques.

Authors:  Van Loi Pham; Misako Nakayama; Yasushi Itoh; Hirohito Ishigaki; Mitsutaka Kitano; Masahiko Arikata; Hideaki Ishida; Naoko Kitagawa; Shintaro Shichinohe; Masatoshi Okamatsu; Yoshihiro Sakoda; Hideaki Tsuchiya; Shinichiro Nakamura; Hiroshi Kida; Kazumasa Ogasawara
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

Review 8.  Serologic vaccination response after solid organ transplantation: a systematic review.

Authors:  Isabella Eckerle; Kerstin Daniela Rosenberger; Marcel Zwahlen; Thomas Junghanss
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.